Eli Lilly’s donanemab gets CHMP backing for early Alzheimer’s in select patients after trials show reduced disease progression and cognitive decline.
Eli Lilly’s Early Alzheimer’s Drug Recommended For Approval By European Drug Regulator’s Panel
Where Today's News Shapes Tomorrow
